Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin

Sixian Liang; Xun Peng; Xiaoli Li; Ping Yang; Linhao Xie; Yaochen Li; Caiwen Du; Guojun Zhang

doi:10.18632/oncotarget.28109

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin

PDF | How to cite

Oncotarget. 2022; 13:583-584. https://doi.org/10.18632/oncotarget.28109

Metrics: PDF 1132 views | ?

Sixian Liang^1,*, Xun Peng^2,*, Xiaoli Li¹, Ping Yang¹, Linhao Xie¹, Yaochen Li³, Caiwen Du¹ and Guojun Zhang³

¹Department of Breast Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515031, PR China
²Department of Radiotherapy, Cancer Hospital of Shantou University Medical College, Shantou 515031, PR China
³The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou 515031, PR China
^*These authors have contributed equally to this work

Published: April 01, 2022

Copyright: © 2022 Liang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 4C, panel ‘o’ contains a partial accidental overlap of panel ‘e’. The corrected Figure 4, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2015; 6:1020–1030. DOI: https://doi.org/10.18632/oncotarget.2741

Figure 4: (C) Immunohistochemical staining of xenograft tumors for p53, Bax, Bcl-2 and caspase-3 (magnification = 40×).

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28109

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin